DexCom NewsMore News
TipRanks
RBC Capital Sticks to Their Buy Rating for Dexcom (DXCM)
InvestorPlace
Should You Buy the 3 Worst Nasdaq 100 Stocks Since the Tech Sector Selloff?
TipRanks
Dexcom (DXCM) Receives a Buy from Wells Fargo
Historical Prices for DexCom
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
DexCom Analyst Data
Total Analysts: 61
Buy Ratings: 39 Neutral Ratings: 22 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 75.00 Median: 127.49 Highest: 165.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
DexCom Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/29/24 | Barclays Capital | Maintained Hold | $113 | neutral | ||
| 07/26/24 | BTIG Research | Maintained Buy | $120 | gut | ||
| 07/26/24 | Morgan Stanley | Maintained Hold | $75 | neutral | ||
| 07/26/24 | Oppenheimer & Co. Inc. | Maintained Buy | $115 | gut | ||
| 07/26/24 | UBS | Maintained Buy | $95 | gut | ||
| 07/26/24 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $90 | gut | ||
| 07/26/24 | Piper Sandler | Maintained Buy | $90 | gut | ||
| 07/26/24 | RBC Capital Markets | Maintained Buy | $145 | gut | ||
| 07/26/24 | Wells Fargo & Co | Maintained Buy | $80 | gut | ||
| 07/26/24 | Capital Depesche | Maintained Buy | $89 | gut | ||
| 07/26/24 | J.P. Morgan | Downgraded to Hold | $75 | neutral | ||
| 07/23/24 | Capital Depesche | Maintained Buy | $145 | gut | ||
| 07/15/24 | Morgan Stanley | Maintained Hold | $120 | neutral | ||
| 07/12/24 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $132 | gut | ||
| 04/26/24 | Raymond James Financial, Inc. | Maintained Buy | $160 | sehr gut | ||
| 04/26/24 | Capital Depesche | Maintained Buy | $145 | gut | ||
| 04/10/24 | UBS | Maintained Buy | $163 | gut | ||
| 04/03/24 | Citigroup Corp. | Maintained Buy | $161 | gut | ||
| 03/12/24 | RBC Capital Markets | Maintained Buy | $165 | gut | ||
| 01/23/24 | Raymond James Financial, Inc. | Maintained Buy | $151 | sehr gut | ||
| 01/03/24 | Raymond James Financial, Inc. | Maintained Buy | $147 | sehr gut | ||
| 12/19/23 | Piper Sandler | Maintained Buy | $150 | gut | ||
| 12/13/23 | Wells Fargo & Co | Maintained Buy | $136 | gut | ||
| 12/04/23 | Morgan Stanley | Maintained Hold | $122 | neutral | ||
| 10/27/23 | Morgan Stanley | Maintained Hold | $101 | neutral | ||
| 10/17/23 | J.P. Morgan | Maintained Buy | $100 | gut | ||
| 10/10/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $145 | gut | ||
| 09/29/23 | Morgan Stanley | Maintained Hold | $98 | neutral | ||
| 09/15/23 | Raymond James Financial, Inc. | Maintained Buy | $131 | sehr gut | ||
| 09/06/23 | UBS | Maintained Buy | $138 | gut | ||
| 08/21/23 | Baird Patrick & Co | Maintained Buy | $130 | gut | ||
| 07/31/23 | Barclays Capital | Maintained Hold | $138 | neutral | ||
| 07/28/23 | Piper Sandler | Maintained Buy | $160 | gut | ||
| 07/28/23 | Capital Depesche | Maintained Buy | $150 | gut | ||
| 07/28/23 | Raymond James Financial, Inc. | Maintained Buy | $154 | sehr gut | ||
| 07/28/23 | Baird Patrick & Co | Maintained Buy | $153 | gut | ||
| 07/11/23 | Citigroup Corp. | Maintained Buy | $150 | gut | ||
| 06/26/23 | BTIG Research | Maintained Buy | $150 | gut | ||
| 05/30/23 | Morgan Stanley | Maintained Hold | $131 | neutral | ||
| 05/01/23 | Barclays Capital | Maintained Hold | $115 | neutral | ||
| 04/28/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $140 | gut | ||
| 04/28/23 | BTIG Research | Maintained Buy | $134 | gut | ||
| 04/28/23 | Capital Depesche | Maintained Buy | $135 | gut | ||
| 04/28/23 | Raymond James Financial, Inc. | Maintained Buy | $140 | sehr gut | ||
| 04/17/23 | BTIG Research | Maintained Buy | $132 | gut | ||
| 04/17/23 | Raymond James Financial, Inc. | Upgraded to Buy | $138 | sehr gut | ||
| 03/29/23 | UBS | Maintained Buy | $142 | gut | ||
| 02/13/23 | Barclays Capital | Maintained Hold | $110 | neutral | ||
| 02/10/23 | Cowen and Company, LLC | Maintained Buy | $125 | gut | ||
| 01/26/23 | Wolfe Research | Maintained Buy | $121 | gut |
DexCom Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 4,013 | 4,639 | 5,392 | 6,335 | 7,301 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | - |
| EPS | 1.70 | 2.01 | 2.42 | 2.94 | 3.57 |
| P/E Ratio | 42.86 | 36.14 | 30.07 | 24.71 | 20.38 |
| EBIT | 799 | 986 | 1,228 | 1,531 | 1,835 |
| EBITDA | 1,109 | 1,338 | 1,622 | 1,965 | 2,488 |
| Net Profit | 693 | 819 | 993 | 1,283 | 1,522 |
| Net Profit Adjusted | 693 | 819 | 993 | 1,283 | 1,522 |
| Pre-Tax Profit | 885 | 1,071 | 1,295 | 1,625 | 1,898 |
| Net Profit (Adjusted) | 934 | 1,004 | 1,165 | - | - |
| EPS (Non-GAAP) ex. SOE | 1.70 | 2.01 | 2.42 | 2.94 | 3.57 |
| EPS (GAAP) | 1.63 | 1.99 | 2.42 | 3.06 | 3.55 |
| Gross Income | 2,524 | 2,989 | 3,528 | 4,157 | 4,804 |
| Cash Flow from Investing | -368 | -501 | -751 | - | - |
| Cash Flow from Operations | 1,022 | 1,228 | 1,495 | - | - |
| Cash Flow from Financing | -368 | -501 | -751 | - | - |
| Cash Flow per Share | 2.46 | 3.15 | 3.92 | - | - |
| Free Cash Flow | 733 | 917 | 1,160 | 1,439 | - |
| Free Cash Flow per Share | 1.73 | 1.99 | 2.55 | 3.22 | 3.91 |
| Book Value per Share | 6.21 | 7.50 | 8.81 | - | - |
| Net Debt | 776 | -42 | -915 | -2,524 | - |
| Research & Development Exp. | 537 | 609 | 699 | 787 | 894 |
| Capital Expenditure | 262 | 293 | 312 | 406 | - |
| Selling, General & Admin. Exp. | 1,213 | 1,393 | 1,573 | 1,844 | 2,120 |
| Shareholder’s Equity | 2,502 | 3,017 | 3,592 | - | - |
| Total Assets | 6,494 | 7,200 | 7,878 | - | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 20 | 20 | 22 | 22 |
| Average Estimate | - | 0.435 USD | 0.516 USD | 1.697 USD | 2.013 USD |
| Year Ago | - | 0.312 USD | 0.667 USD | 1.403 USD | - |
| Publish Date | - | 10/24/2024 | 2/6/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 20 | 20 | 22 | 22 |
| Average Estimate | - | 989 USD | 1,100 USD | 4,013 USD | 4,639 USD |
| Year Ago | - | 975 USD | 1,035 USD | 3,622 USD | - |
| Publish Date | - | 10/24/2024 | 2/6/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 3,622.30 | 2,909.80 | 2,448.50 | 1,926.70 | 1,476.00 | 1,031.60 | 718.50 |
| Change of sales in % | 24.49 | 18.84 | 27.08 | 30.54 | 43.08 | 43.58 | 25.33 |
| Gross profit on sales | 2,280.80 | 1,875.60 | 1,680.50 | 1,280.10 | 931.50 | 663.90 | 492.10 |
| Gross profit on sales change in % | 21.60 | 11.61 | 31.28 | 37.42 | 40.31 | 34.91 | 30.05 |
| Operating income | 597.70 | 391.20 | 265.80 | 299.50 | 142.30 | -180.90 | -33.30 |
| Operating income change in % | 52.79 | 47.18 | -11.25 | 110.47 | - | -443.24 | 47.89 |
| Income before tax | 710.40 | 390.80 | 173.90 | 225.00 | 104.20 | -126.50 | -48.60 |
| Income before tax change in % | 81.78 | 124.73 | -22.71 | 115.93 | - | -160.29 | 25.12 |
| Income after tax | 541.50 | 341.20 | 154.70 | 493.60 | 101.10 | -127.10 | -50.20 |
| Income after tax change in % | 58.70 | 120.56 | -68.66 | 388.23 | - | -153.19 | 23.48 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 4,195.90 | 3,259.90 | 2,612.10 | 2,556.20 | 1,512.40 | 1,252.70 | 484.70 |
| Long-term liabilities per share | 6.85 | 3.68 | 4.86 | 5.05 | 3.14 | 2.86 | 0.99 |
| Equity | 2,068.60 | 2,131.80 | 2,251.50 | 1,826.50 | 882.60 | 663.30 | 419.40 |
| Equity change in % | -2.96 | -5.32 | 23.27 | 106.95 | 33.06 | 58.15 | 47.78 |
| Balance sheet total | 6,264.50 | 5,391.70 | 4,863.60 | 4,382.70 | 2,395.00 | 1,916.00 | 904.10 |
| Balance sheet total change in % | 16.19 | 10.86 | 10.97 | 82.99 | 25.00 | 111.92 | 124.45 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 8.51 | 6.81 | 6.12 | 4.94 | 4.00 | 2.92 | 2.08 |
| P/E ratio (year end quote, basic EPS) | 95.29 | 141.89 | 347.41 | 73.03 | 199.73 | - | - |
| P/E ratio (year end quote, diluted EPS) | 95.29 | 141.89 | 347.41 | 73.03 | 199.73 | - | - |
| P/E ratio (year end quote) | 95.29 | 141.89 | 347.41 | 73.03 | 199.73 | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 33.02 | 39.54 | 46.29 | 41.68 | 36.85 | 34.62 | 46.39 |
| Debt ratio in % | 66.98 | 60.46 | 53.71 | 58.32 | 63.15 | 65.38 | 53.61 |
DexCom Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Brown Michael Jon | 07/30/2024 | 652.00 | 66,249.00 | 69.55 | Sell | No |
| Brown Michael Jon | 06/27/2024 | 659.00 | 66,901.00 | 114.29 | Sell | No |
| FOLETTA MARK G | 06/17/2024 | 299.00 | 56,398.00 | 117.25 | Sell | No |
| FOLETTA MARK G | 06/17/2024 | 3,007.00 | 56,697.00 | 116.75 | Sell | No |
| FOLETTA MARK G | 06/16/2024 | 475.00 | 59,704.00 | 117.77 | Sell | No |
| FOLETTA MARK G | 06/16/2024 | 7.00 | 62,391.00 | 115.18 | Sell | No |
| FOLETTA MARK G | 06/16/2024 | 2,212.00 | 60,179.00 | 117.16 | Sell | No |
| Driscoll Rimma | 05/21/2024 | 2,632.00 | 6,640.00 | n/a | Buy | No |
| FOLETTA MARK G | 05/21/2024 | 2,973.00 | 2,973.00 | n/a | Buy | No |
| TOPOL ERIC | 05/21/2024 | 2,618.00 | 2,618.00 | n/a | Buy | No |
| Malady Kyle | 05/21/2024 | 2,613.00 | 18,142.00 | n/a | Buy | No |
| AUGUSTINOS NICHOLAS | 05/21/2024 | 2,618.00 | 2,618.00 | n/a | Buy | No |
| ALTMAN STEVEN R | 05/21/2024 | 2,613.00 | 2,613.00 | n/a | Buy | No |
| Heller Bridgette P | 05/21/2024 | 2,618.00 | 26,349.00 | n/a | Buy | No |
| Collins Richard Alexander | 05/21/2024 | 2,632.00 | 2,632.00 | n/a | Buy | No |
| Dahut Karen M | 05/21/2024 | 2,613.00 | 2,613.00 | n/a | Buy | No |
| FOLETTA MARK G | 05/17/2024 | 3,306.00 | n/a | n/a | Sell | No |
| Collins Richard Alexander | 05/17/2024 | 2,906.00 | n/a | n/a | Sell | No |
| ALTMAN STEVEN R | 05/17/2024 | 2,885.00 | n/a | n/a | Sell | No |
| TOPOL ERIC | 05/17/2024 | 2,911.00 | n/a | n/a | Sell | No |
| AUGUSTINOS NICHOLAS | 05/17/2024 | 3,043.00 | n/a | n/a | Sell | No |
| Dahut Karen M | 05/17/2024 | 2,906.00 | n/a | n/a | Sell | No |
| KAHN BARBARA | 05/17/2024 | 2,927.00 | n/a | n/a | Sell | No |
| FOLETTA MARK G | 05/17/2024 | 3,306.00 | 62,398.00 | n/a | Buy | No |
| ALTMAN STEVEN R | 05/17/2024 | 2,885.00 | 56,017.00 | n/a | Buy | No |
DexCom Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2022 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2021 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2020 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2019 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2018 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2017 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2016 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2015 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2014 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2013 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2012 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2011 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2010 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2009 | DexCom Inc. | 0.00 | 0.00 | USD |
*Yield of the Respective Date
DexCom Inc. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.435 USD | Q3 2024 Earnings Release | 10/24/2024 |
| Earnings Report | 0.516 USD | Q4 2024 Earnings Release | 02/06/2025 |
| Earnings Report | 0.397 USD | Q1 2025 Earnings Release | 04/24/2025 |
| Earnings Report | 0.474 USD | Q2 2025 Earnings Release | 07/24/2025 |
DexCom Inc. Past Events
| Event | Actual EPS | Info | Date |
|---|
DexCom Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
DexCom Shareholder
| Owner | in % |
|---|---|
| Freefloat | 98.47 |
| Vanguard Group, Inc. (Subfiler) | 11.17 |
| The Vanguard Group, Inc. | 11.10 |
| State Street Corp. | 4.07 |
| Baillie Gifford & Co. | 3.82 |
| BlackRock Fund Advisors | 3.70 |
| Vanguard Total Stock Market ETF | 3.13 |
| Capital Research & Management Co. (Global Investors) | 2.98 |
| Sands Capital Management LLC | 2.65 |
| Vanguard 500 Index Fund | 2.58 |
| Geode Capital Management LLC | 2.43 |
| BlackRock Institutional Trust Co. NA | 2.16 |
| Vanguard Mid Cap Index Fund | 2.12 |
| Capital Research & Management Co. (World Investors) | 2.07 |
| Invesco QQQ Trust | 1.93 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
DexCom Management
| Name | Job |
|---|---|
| Kevin Ronald Sayer | Chairman, President & Chief Executive Officer |
| Teri L. Lawver | Chief Commercial Officer & Executive VP |
| Jereme M Sylvain | Chief Financial Officer & Executive Vice President |
| Sadie M Stern | Chief Human Resources Officer & Executive VP |
| Shelly R. Selvaraj | Chief Information Officer & Senior Vice President |
| Michael Jon Brown | Chief Legal Officer & Executive Vice President |
| Jacob S. Leach | Chief Operating Officer & Executive Vice President |
| Girish Naganathan | Chief Technology Officer & Executive VP |
| Steven Robert Pacelli | Executive VP & Managing Director-Dexcom Ventures |
| Donald M. Abbey | Executive VP-IT Quality & Regulatory Affairs |
| Matt V. Dolan | Executive VP-Strategy & Corporate Development |
| Barry J. Regan | Executive Vice President-Global Operations |
| Paul R. Flynn | Executive Vice President-Global Revenue |
| Karen M. Dahut | Independent Director |
| Richard Alexander Collins | Independent Director |
| Steven R. Altman | Independent Director |
| Kyle J. Malady | Independent Director |
| Rimma Driscoll | Independent Director |
| Nicholas Augustinos | Independent Director |
| Bridgette P. Heller | Independent Director |
| Eric J. Topol | Independent Director |
| Mark G. Foletta | Lead Independent Director |
| Sean Christensen | Vice President-Finance & Investor Relations |
